ERBB2 and neoplasm: However, there is still no reliable means of risk stratifying HER2-positive and triple-negative tumours and, consequently, there is a push towards chemotherapy and targeted therapy even for the treatment of small tumours, largely because of the proven efficacy of anti-HER2 therapies in the former and the lack of any other systemic alternative in the latter.